Gene Editing Therapies Bibliometric Analysis, 2005-2025

1,571 peer-reviewed articles and reviews on gene editing therapies for human genetic diseases were analyzed from 2005 to 2025. The bibliometric study by Xinhao Zhou, published on figshare in 2026, maps the field's evolution from engineered nucleases to CRISPR and precision translation. It identifies leading disease targets, institutional hubs, and emerging frontiers like base editing and AI-assisted design.

Use Cases

• Mapping research collaboration networks based on the bibliometric analysis of publication data.
• Identifying leading disease targets and therapeutic strategies based on the analysis of publication focus areas.
• Analyzing the translational trajectory of gene editing technologies from bench to bedside based on the three-phase growth model described.
• Studying geographic and institutional productivity based on the identified dominance of the United States, China, Harvard, and the University of California.

Strengths

• Analysis is based on 1,571 peer-reviewed articles and reviews, providing a substantial corpus.
• Covers a 20-year time range from 2005 to 2025, capturing the field's evolution.
• Uses established bibliometric tools like CiteSpace and VOSviewer for science mapping.

Limitations

• The dataset is a 14.2 KB DOCX file, suggesting limited raw data scope; the full analysis results may not be machine-readable.
• Row count and column-level documentation are absent, limiting suitability assessment for quantitative reuse.
• Data may reflect publication bias inherent to the Web of Science Core Collection and Scopus sources.

Provenance

Source

Articles retrieved from Web of Science Core Collection and Scopus.

Collection Method

Bibliometric analysis and science mapping using CiteSpace and VOSviewer.

Time Range

2005 to 2025

Freshness

Last updated 2026-06-03 04:26:47; freshness should be verified.

Geography

Global, with noted dominance from the United States and China.